Recently, several translational studies have suggested that resistance to tyrosine kinase inhibitor treatment might confer a favorable tumor immune microenvironment for subsequent immunotherapy owing to an increase in PD-L1 expression in tumor and immune cells as well as the density of tumor-infiltrating lymphocytes [12, 33, 34]. This evidence concerns the gene CD274 and neoplasm.